2022
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Cancer
PubMed • Publisher's siteResearch at a glance
Top areas of exploration
- Pregnancy , 14 publications
- Cell Line, Tumor , 10 publications
- Uterine Neoplasms , 8 publications
- Neoplasm Recurrence, Local , 7 publications
Research activity
My publications
Filter publications
80 publications
2022
Alterations in Pre/Post Oxygenator Flows Due to Fibrin Deposition in the CardioHelp System-A Case Report.
The journal of extra-corporeal technology
PubMed • Publisher's site2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
British journal of cancer
PubMed • Publisher's site2021
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Annals of oncology : official journal of the European Society for Medical Oncology
PubMed • Publisher's site2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Gynecologic oncology
PubMed • Publisher's site